## Abstract ## BACKGROUND Women with metastatic breast carcinoma have a highly variable clinical course and outcome. Intrinsic genetic heterogeneity of the primary breast tumor may play a role in this variability and may explain it in part. Therefore, the authors tested the hypothesis that the cha
Evaluation of six tumor markers in patients with carcinoma of unknown primary
β Scribed by Pavlidis, Nicholas ;Kalef-Ezra, John ;Briassoulis, Evangelos ;Skarlos, Dimosthenis ;Kosmidis, Paris ;Saferiadis, Kostas ;Bairaktari, Eleni ;Bafaloukos, Dimitrios ;Maravegias, Athanassios ;Theoharis, Dimitrios ;Fountzilas, George
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 494 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
We have retrospectively evaluated six serum tumor markers in 85 patients with carcinoma of unknown primary. The serum levels of carcinoembryonic antigen (CEA), CA 19β9, CA 15β3, CA 125, Ξ²βchorionic gonadotropin (Ξ²βHCG) and Ξ±βfetoprotein (AFP) were related with the histological pattern (undifferentiated carcinoma or adenocarcinoma), the number and the site of metastases, as well as the response to chemotherapy and the patients' survival. More than 40% of the patients had increased serum levels of all six tumor markers, except of AFP which was found to be increased in only 17% of them. Increased levels of CA 19β9 were related to metastatic adenocarcinoma, whereas CA 19β9 and CA 15β3 had a relationship with more advanced disease. Patients with liver involvement had higher mean levels of CEA and CA 19β9 as compared to those with nodal disease. None of these markers was found to have a predictive value for response to chemotherapy or survival.
Although the present study has a retrospective nature, it allows us to conclude that patients with CUP have a nonspecific overβexpression of the above serum tumor markers and that routine use of these markers does not offer any diagnostic or prognostic assistance. Β© 1994 wileyβLiss, lnc.
π SIMILAR VOLUMES
Numerous ectopic hormones and markers have been described in small cell carcinoma of the lung as well as in extrapulmonary small cell carcinomas. The authors report a case of a patient with metastatic small cell carcinoma of unknown primary who had very high prostatic acid phosphatase (PAP) and pros
W e read with interest the results from the study of serum albu- min and liver metastasis in patients with carcinomas of unknown primary site by Seve et al. 1 We can present some results from our unpublished study in patients with cancer of unknown primary site in which we explored a set of possible
## Abstract ## BACKGROUND. The purposes of this study were to evaluate efficacy and toxicity of the combination of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site (CUP). ## METHODS. Patients with CUP received carboplatin AUC 5 mg/mL a minute intraven